Processing of amyloid precursor protein and amyloid peptide neurotoxicity

Current Alzheimer Research

Volumn 5, Issue 2, 2008, Pages 92-99

  Nathalie, Pierrot ^a   Jean Noël, Octave ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Alzheimer's disease; Amyloid peptide; APP; Cell lines; Neuron; Phosphorylation; Processing; Tau; Toxicity

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CELL TYPE; HUMAN; NERVE CELL CULTURE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; SENILE PLAQUE;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; NEURONS; NEUROTOXICITY SYNDROMES; PHOSPHORYLATION; TRANSFECTION;

EID: 42149164312     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783954721     Document Type: Review

References (147)

1. Qiu C, De Ronchi D and Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 20: 380-385 (2007).
2. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 59: 1737-1746 (2002).
3. Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890 (1984).
4. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82: 4245-4249 (1985).
5. Brion JP, Couck AM, Passareiro E and Flament-Durand J. Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol 17: 89-96 (1985).
6. Delacourte A and Defossez A. Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci 76: 173-186 (1986).
7. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM and Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83: 4913-4917 (1986).
8. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
9. Octave JN. The amyloid peptide and its precursor in Alzheimer's disease. Rev Neurosci 6: 287-316 (1995).
10. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927 (1999).
11. Allinson TM, Parkin ET, Turner AJ and Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 74: 342-352 (2003).
12. Schlondorff J and Blobel CP. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 112 (Pt 21): 3603-3617 (1999).
13. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE [see comments]. Science 286: 735-741 (1999).
14. Wilquet V and De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14: 582-588 (2004).
15. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain [see comments]. Nature 402: 537-540 (1999).
16. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta- secretase activity. Nature 402: 533-537 (1999).
17. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14: 419-427 (1999).
18. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active gamma- Secretase Complex. Neuron 38: 9-12 (2003).
19. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H and Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol 5: 486-488 (2003).
20. Cao X and Sudhof TC. A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115-120 (2001).
21. Cao X and Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 279: 24601-24611 (2004).
22. Von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J Cell Sci 117: 4435-4448 (2004).
23. Zhang YW, Wang R, Liu Q, Zhang H, Liao FF and Xu H. Presenilin/{gamma}- secretase-dependent processing of {beta}-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 104: 10613-8 (2007).
24. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK and Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110: 55-67 (2002).
25. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves dC, Vincent B, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 46: 541-554 (2005).
26. Muller T, Concannon CG, Ward MW, Walsh CM, Tirniceriu AL, Tribl F, et al. Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol Biol Cell 18: 201-210 (2007).
27. Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY and Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 3: 159-16 (1996).
28. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20: 154-159 (1997).
29. Tanzi RE and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555 (2005).
30. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
31. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908-22914 (1996).
32. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer's disease by beta- secretase cleavage within the secretory pathway. Nat Med 1: 1291-1296 (1995).
33. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5: 101-106 (1999).
34. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13: 159-170 (2004).
35. Piccini A, Zanusso G, Borghi R, Noviello C, Monaco S, Russo R, et al. Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch Neurol 64: 738-745 (2007).
36. Zhang Y, McLaughlin R, Goodyer C and LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156: 519-529 (2002).
37. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, et al. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87: 609-619 (2003).
38. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG and Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676-1687 (1993).
39. Kienlen-Campard P, Miolet S, Tasiaux B and Octave JN. Intracellular Amyloid-beta 1-42, but Not Extracellular Soluble Amyloid-beta Peptides, Induces Neuronal Apoptosis. J Biol Chem 277: 15666-15670 (2002).
40. Pierrot N, Ghisdal P, Caumont AS and Octave JN. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem 88: 1140-1150 (2004).
41. Perez RG, Squazzo SL and Koo EH. Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. J Biol Chem 271: 9100-9107 (1996).
42. Rebelo S, Henriques AG, da Cruz e Silva EF and da Cruz E Silva OA. Effect of cell density on intracellular levels of the Alzheimer's amyloid precursor protein. J Neurosci Res 76: 406-414 (2004).
43. Petanceska SS, Seeger M, Checler F and Gandy S. Mutant presenilin 1 increases the levels of Alzheimer amyloid beta-peptide Abeta42 in late compartments of the constitutive secretory pathway. J Neurochem 74: 1878-1884 (2000).
44. Flood F, Murphy S, Cowburn RF, Lannfelt L, Walker B and Johnston JA. Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. Biochem J 385: 545-550 (2005).
45. Armogida M, Petit A, Vincent B, Scarzello S, da Costa CA and Checler F. Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat Cell Biol 3: 1030-1033 (2001).
46. Petit A, George-Hyslop P, Fraser P and Checler F. Gammasecretase-like cleavages of Notch and beta APP are mutually exclusive in human cells. Biochem Biophys Res Commun 290: 1408-1410 (2002).
47. Kienlen-Campard P, Tasiaux B and Octave J. The processing and biological function of the human amyloid precursor protein (APP): lessons from different cellular models [In Process Citation]. Exp Gerontol 35: 843-850 (2000).
48. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P and Selkoe DJ. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 93: 13170-13175 (1996).
49. Wilson CA, Doms RW, Zheng H and Lee VM. Presenilins are not required for A beta 42 production in the early secretory pathway. Nat Neurosci 5: 849-855 (2002).
50. Jarrett JT, Berger EP and Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697 (1993).
51. Grimm HS, Beher D, Lichtenthaler SF, Shearman MS, Beyreuther K and Hartmann T. gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J Biol Chem 278: 13077-13085 (2003).
52. Wang YP, Wang XC, Tian Q, Yang Y, Zhang Q, Zhang JY, et al. Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells. J Neural Transm 113: 1723-1732 (2006).
53. Takeda K, Araki W and Tabira T. Enhanced generation of intracellular Abeta42 amyloid peptide by mutation of presenilins PS1 and PS2. Eur J Neurosci 19: 258-264 (2004).
54. Fang B, Jia L and Jia J. Chinese Presenilin-1 V97L mutation enhanced Abeta42 levels in SH-SY5Y neuroblastoma cells. Neurosci Lett 406: 33-37 (2006).
55. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, et al. Estrogen reduces neuronal generation of Alzheimer betaamyloid peptides. Nat Med 4: 447-451 (1998).
56. De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K and Dotti CG. Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. EMBO J 14: 4932-4938 (1995).
57. Tienari PJ, Ida N, Ikonen E, Simons M, Weidemann A, Multhaup G, et al. Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc Natl Acad Sci USA 94: 4125-4130 (1997).
58. Olkkonen VM, Liljestrom P, Garoff H, Simons K and Dotti CG. Expression of heterologous proteins in cultured rat hippocampal neurons using the Semliki Forest virus vector. J Neurosci Res 35: 445-451 (1993).
59. Macq AF, Czech C, Essalmani R, Brion JP, Maron A, Mercken L, et al. The long term adenoviral expression of the human amyloid precursor protein shows different secretase activities in rat cortical neurons and astrocytes. J Biol Chem 273: 28931-28936 (1998).
60. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908-22914 (1996).
61. Bayer TA, Wirths O, Majtenyi K, Hartmann T, Multhaup G, Beyreuther K, et al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 11: 1-11 (2001).
62. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid- beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406 (1999).
63. Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5: 560-564 (1999).
64. Knobloch M, Konietzko U, Krebs DC and Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28: 1297-1306 (2007).
65. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, et al. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7: 609-618 (2001).
66. Li QX, Maynard C, Cappai R, McLean CA, Cherny RA, Lynch T, et al. Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J Neurochem 72: 2479-2487 (1999).
67. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L and Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 27: 67-77 (2006).
68. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26: 10129-10140 (2006).
69. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, et al. Intraneuronal Abeta accumulation precedes plaque formation in beta- amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 306: 116-120 (2001).
70. Oddo S, Caccamo A, Kitazawa M, Tseng BP and LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070 (2003).
71. Billings LM, Oddo S, Green KN, McGaugh JL and LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's diseaserelated cognitive deficits in transgenic mice. Neuron 45: 675-688 (2005).
72. Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA 99: 6334-6339 (2002).
73. Kitazawa M, Green KN, Caccamo A and LaFerla FM. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 168: 1986-1997 (2006).
74. Moussa CE, Fu Q, Kumar P, Shtifman A, Lopez JR, Allen PD, et al. Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J 20: 2165-2167 (2006).
75. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156: 15-20 (2000).
76. Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y and Shoji S. Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet 355: 42-43 (2000).
77. Nagele RG, D'Andrea MR, Anderson WJ and Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110: 199-211 (2002).
78. D'Andrea MR, Nagele RG, Wang HY, Peterson PA and Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38: 120-134 (2001).
79. D'Andrea MR, Nagele RG, Wang HY and Lee DH. Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. Neurosci Lett 333: 163-166 (2002).
80. D'Andrea MR, Nagele RG, Gumula NA, Reiser PA, Polkovitch DA, Hertzog BM, et al. Lipofuscin and Abeta42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci Lett 323: 45-49 (2002).
81. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH and Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100: 310-320 (1997).
82. Shie FS, LeBoeuf RC and Jin LW. Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport 14: 123-129 (2003).
83. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. Nature 395: 755-756 (1998).
84. Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, et al. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol Chem 272: 16085-16088 (1997).
85. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, et al. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3: 1021-1023 (1997).
86. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT, Jr. and Kosik KS. A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 4: 730-734 (1998).
87. Skovronsky DM, Doms RW and Lee VM. Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol 141: 1031-1039 (1998).
88. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 3: 1016-1020 (1997).
89. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869-1879 (2002).
90. Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, et al. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol 165: 1465-1477 (2004).
91. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP and Reitz AB. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275: 5626-5632 (2000).
92. Bu G, Cam J and Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086: 35-53 (2006).
93. Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913 (2003).
94. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691 (1996).
95. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 888: 256-262 (2001).
96. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051-1058 (2005).
97. Walsh DM, Tseng BP, Rydel RE, Podlisny MB and Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39: 10831-10839 (2000).
98. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 281: 1599-1604 (2006).
99. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539 (2002).
100. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267: 546-554 (1992).
101. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8: 447-453 (1998).
102. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870 (1996).
103. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42- residue amyloid beta-protein in both transfected cells and transgenic mice [see comments]. Nat Med 3: 67-72 (1997).
104. Liu K, Doms RW and Lee VM. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. Biochemistry 41: 3128-3136 (2002).
105. Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, et al. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol (Berl) 112: 163-174 (2006).
106. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P and Teller JK. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 409: 411-416 (1997).
107. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y and Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14: 457-466 (1995).
108. Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, et al. Presenilin-1 mutations in Alzheimer's disease. Nature 405: 531-532 (2000).
109. Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 45: 5503-5516 (2006).
110. Katzman R. Alzheimer's disease. N Engl J Med 314: 964-973 (1986).
111. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580 (1991).
112. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I and Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16: 285-298 (1995).
113. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483-6492 (1999).
114. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 3228-3233 (1999).
115. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2: 271-276 (1999).
116. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058 (2000).
117. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22: 1858-1867 (2002).
118. Dineley KT, Xia X, Bui D, Sweatt JD and Zheng H. Accelerated plaque accumulation, associative learning deficits, and upregulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 277: 22768-22780 (2002).
119. Wu CC, Chawla F, Games D, Rydel RE, Freedman S, Schenk D, et al. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci USA 101: 7141-7146 (2004).
120. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27: 627-633 (2007).
121. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440: 528-534 (2006).
122. da Cruz e Silva EF and da Cruz e Silva OA. Protein phosphorylation and APP metabolism. Neurochem Res 28: 1553-1561 (2003).
123. Small SA and Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 52: 15-31 (2006).
124. Ando K, Iijima KI, Elliott JI, Kirino Y and Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem 276: 40353-40361 (2001).
125. Buxbaum JD, Koo EH and Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc Natl Acad Sci USA 90: 9195-9198 (1993).
126. Gandy S, Czernik AJ and Greengard P. Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Proc Natl Acad Sci USA 85: 6218-6221 (1988).
127. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC and Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J 13: 1114-1122 (1994).
128. Tarr PE, Contursi C, Roncarati R, Noviello C, Ghersi E, Scheinfeld MH, et al. Evidence for a role of the nerve growth factor receptor TrkA in tyrosine phosphorylation and processing of beta-APP. Biochem Biophys Res Commun 295: 324-329 (2002).
129. Zambrano N, Bruni P, Minopoli G, Mosca R, Molino D, Russo C, et al. The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene. J Biol Chem 276: 19787-19792 (2001).
130. Liu F, Su Y, Li B, Zhou Y, Ryder J, Gonzalez-DeWhitt P, et al. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett 547: 193-196 (2003).
131. Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, et al. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem 75: 1085-1091 (2000).
132. Oishi M, Nairn AC, Czernik AJ, Lim GS, Isohara T, Gandy SE, et al. The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Mol Med 3: 111-123 (1997).
133. Phiel CJ, Wilson CA, Lee VM and Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439 (2003).
134. Ryder J, Su Y, Liu F, Li B, Zhou Y and Ni B. Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312: 922-929 (2003).
135. Pierrot N, Santos SF, Feyt C, Morel M, Brion JP and Octave JN. Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. J Biol Chem 281: 39907-39914 (2006).
136. Feyt C, Pierrot N, Tasiaux B, Van Hees J, Kienlen-Campard P, Courtoy PJ, et al. Phosphorylation of APP695 at Thr668 decreases gamma-cleavage and extracellular Abeta. Biochem. Biophys Res Commun 357: 1004-1010 (2007).
137. Vingtdeux V, Hamdane M, Gompel M, Begard S, Drobecq H, Ghestem A, et al. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma secretase-dependent mechanism. Neurobiol Dis 20: 625-637 (2005).
138. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, et al. Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163: 83-95 (2003).
139. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM and Anderton BH. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 67: 699-707 (1996).
140. Standen CL, Brownlees J, Grierson AJ, Kesavapany S, Lau KF, McLoughlin DM, et al. Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). J Neurochem 76: 316-320 (2001).
141. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97: 2910-2915 (2000).
142. Hanger DP, Hughes K, Woodgett JR, Brion JP and Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147: 58-62 (1992).
143. Hartigan JA and Johnson GV. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem 274: 21395-21401 (1999).
144. Paglini G and Caceres A. The role of the Cdk5 - p35 kinase in neuronal development. Eur J Biochem 268: 1528-1533 (2001).
145. Shea TB and Ekinci FJ. Biphasic Effect of calcium influx on tau phosphorylation: phosphorylation: biphasic effect of calcium influx on tau phosphorylation: involvement of calcium-dependent phosphatase and kinase activities. J Alzheimers Dis 1: 353-360 (1999).
146. Lesort M, Jope RS and Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 72: 576-584 (1999).
147. Hong M, Chen DC, Klein PS, Lee VM. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272: 25326-25332 (1997).